PDUFA meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA to hear stakeholder testimony Dec. 7 in Bethesda, Md., on what aspects of user fee program should be retained or changed and whether program should allow use of user fee funding to monitor post-approval drug safety. Agency also seeks input on how it can ensure PDUFA goals are met in wake of continued funding shortfalls and whether there should be flexibility in setting user fees to cover increased program costs. PDUFA legislative authority sunsets in September 2002; FDA held a similar public meeting last year (1"The Tan Sheet" Sept. 25, 2000, p. 8)...